Ozempic Gallbladder Disease: Qualifying Injuries in the GLP-1 MDL

Gallbladder disease is one of the most common serious injuries linked to GLP-1 receptor agonist drugs, and it is a qualifying injury in the GLP-1 multidistrict litigation. Thousands of patients who took Ozempic, Wegovy, Mounjaro, or other GLP-1 drugs have developed gallstones, cholecystitis (gallbladder inflammation), or required cholecystectomy (surgical removal of the gallbladder). The FDA has acknowledged the risk in its own labeling requirements, and the evidence connecting GLP-1 drugs to gallbladder disease continues to grow.

How GLP-1 Drugs Cause Gallbladder Disease

The connection between GLP-1 drugs and gallbladder disease is driven by two related mechanisms:

Rapid Weight Loss

GLP-1 receptor agonists can cause significant, rapid weight loss — often 15-20% of body weight over months. Rapid weight loss is a well-established risk factor for gallstone formation. When the body loses weight quickly, the liver secretes excess cholesterol into bile, and the gallbladder does not empty as efficiently. This creates conditions for cholesterol to crystallize into gallstones.

Direct Effect on Gallbladder Motility

GLP-1 receptors are present in the gallbladder. Research suggests that GLP-1 receptor agonists may directly reduce gallbladder motility — the gallbladder’s ability to contract and empty bile. Reduced motility leads to bile stasis (bile sitting in the gallbladder), which promotes stone formation. This is the same type of motility impairment that causes gastroparesis in the stomach.

Types of Qualifying Gallbladder Injuries

Cholelithiasis (Gallstones)

Gallstones are hardened deposits — usually cholesterol-based — that form in the gallbladder. Symptoms include:

• Biliary colic — episodes of intense pain in the upper right abdomen, often after eating fatty foods
• Nausea and vomiting
• Pain radiating to the back or right shoulder

Some gallstones are asymptomatic and discovered incidentally on imaging. Symptomatic gallstones that required medical treatment or surgery are the basis for legal claims.

Cholecystitis (Gallbladder Inflammation)

Cholecystitis occurs when a gallstone becomes lodged in the cystic duct — the tube that connects the gallbladder to the bile duct — blocking the flow of bile. This blockage causes the gallbladder to become inflamed and, in severe cases, infected. Symptoms include:

• Severe, persistent abdominal pain (not just episodic colic)
• Fever and chills
• Tenderness in the upper right abdomen
• Nausea and vomiting

Acute cholecystitis is a medical emergency that often requires hospitalization and urgent surgery.

Cholecystectomy (Gallbladder Removal Surgery)

When gallstones or cholecystitis become severe or recurrent, the standard treatment is surgical removal of the gallbladder. Cholecystectomy is one of the most common surgeries in the United States, but it is not without consequences:

• Laparoscopic cholecystectomy — the less invasive approach, performed through small incisions, with a typical recovery of 1-2 weeks
• Open cholecystectomy — required in complicated cases, involving a larger incision and longer recovery
• Post-cholecystectomy syndrome — some patients experience ongoing digestive problems after gallbladder removal, including diarrhea, bloating, and intolerance to fatty foods

Choledocholithiasis (Common Bile Duct Stones)

In some cases, gallstones migrate from the gallbladder into the common bile duct, causing:

• Jaundice (yellowing of the skin and eyes)
• Pancreatitis — if the stone blocks the pancreatic duct
• Cholangitis — a serious, potentially life-threatening bile duct infection

These complications often require emergency intervention, including endoscopic retrograde cholangiopancreatography (ERCP) to remove the stone.

FDA Warnings on Gallbladder Risk

The FDA has required gallbladder-related warnings on GLP-1 drug labels, but plaintiffs in the litigation allege these warnings have been inadequate. Key points:

• Ozempic’s label includes warnings about cholelithiasis in the Warnings and Precautions section
• Wegovy’s label explicitly warns that “substantial or rapid weight loss can increase the risk of cholelithiasis”
• Clinical trial data submitted to the FDA showed elevated rates of gallbladder events in GLP-1 drug users compared to placebo groups
• Post-market data from the FDA’s FAERS database has shown a significant volume of gallbladder adverse event reports associated with GLP-1 drugs

The legal theory is that while some label warnings existed, they understated the severity and frequency of gallbladder complications and failed to provide adequate guidance to prescribers about monitoring and prevention.

What Medical Evidence You Need

For a gallbladder disease claim in the GLP-1 litigation, the following documentation strengthens your case:

• Prescription records — documentation that you were prescribed and took a GLP-1 medication
• Imaging studies — ultrasound, CT scan, or MRCP showing gallstones or gallbladder inflammation
• Surgical records — operative report from cholecystectomy, if applicable
• Pathology report — analysis of the removed gallbladder confirming cholelithiasis or cholecystitis
• Emergency department records — if you sought emergency treatment for biliary colic, cholecystitis, or related complications
• Timeline evidence — documentation showing your gallbladder problems developed during or after GLP-1 drug use
• Absence of prior gallbladder disease — medical records showing no gallbladder issues before starting the GLP-1 drug strengthen the causal connection

Case Strength Factors

Not all gallbladder cases carry the same weight in the litigation. Factors that strengthen your claim include:

• Cholecystectomy — cases requiring surgery are generally stronger than those managed conservatively
• Emergency presentation — acute cholecystitis or bile duct complications requiring urgent intervention demonstrate the severity of the injury
• No prior gallbladder history — if you had no gallbladder problems before taking the GLP-1 drug, the temporal connection is stronger
• Documented rapid weight loss — medical records showing significant weight loss during GLP-1 use support the mechanistic connection
• Complications — post-surgical complications, bile duct injuries, pancreatitis secondary to gallstones, or other downstream effects increase the severity and value of the claim

Frequently Asked Questions

Is gallbladder removal considered a serious enough injury for a lawsuit?

Yes. Cholecystectomy is a surgery with real risks, recovery time, and lasting consequences. Many patients experience ongoing digestive issues after gallbladder removal. The surgery itself, combined with the pain and medical treatment leading up to it, constitutes a compensable injury in the litigation.

What if I already had gallstones before taking a GLP-1 drug?

A pre-existing history of gallstones does not automatically disqualify your claim, but it may complicate the causation analysis. If your gallbladder disease worsened significantly after starting a GLP-1 drug — for example, if asymptomatic stones became symptomatic, or if you developed cholecystitis for the first time — you may still have a viable claim.

Can I file a gallbladder claim if I also have gastroparesis?

Yes. Multiple injuries from the same drug can be included in a single claim. In fact, having multiple qualifying injuries may increase the overall value of your case. Both gastroparesis and gallbladder disease are recognized injuries in the MDL.

How does a gallbladder claim compare in value to a gastroparesis claim?

Case value depends on individual circumstances, but generally, cases involving cholecystectomy and significant complications are valued meaningfully within the settlement framework. Cases with multiple injuries, emergency treatment, and lasting effects on quality of life are the strongest. Your attorney can evaluate the specific factors in your case.

Do I need to have stopped taking the GLP-1 drug to file a claim?

No. You can file a claim whether you are currently taking the medication or have already stopped. If you are still taking the drug and experiencing gallbladder symptoms, discuss the risks with your doctor — but do not stop any medication without medical guidance.

Take the Next Step

Gallbladder disease caused by GLP-1 drugs is a serious, well-documented injury with strong support in the medical literature and the FDA’s own safety data. If you or a loved one developed gallstones, cholecystitis, or required gallbladder surgery after taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication, you may be entitled to significant compensation.

If you’ve been affected, request a free case review today.

Advertisement. This content is provided for informational purposes only and does not constitute legal advice. NuLegal | Ashkaan Hassan, Esq. | CA Bar #283629